Novo Nordisk's oral weight-loss drug Wegovy is rapidly gaining traction, with US weekly prescriptions surpassing 200,000, positioning it as a potential multi-blockbuster product. UBS raised its sales forecast to $2.2 billion for the year, up from $1.8 billion, following strong first-quarter results where operating profit rose 77% year-on-year. The pill is priced attractively compared to the injectable version and is mainly sold as a cash-pay product, driving faster uptake. However, competition is intensifying, and concerns remain about the company's reliance on semaglutide as the main active molecule. Novo plans to launch the oral pill internationally in the second half of the year and has adjusted its full-year guidance to reflect stronger pill sales offset by pricing pressures on other products.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
